Table 1

Summary of studies demonstrating a type I interferon signature in dermatomyositis muscle or blood

Reference

Array format (approximate number of genes) or other platform

Tissue

Sample size


Tezak and colleagues [4]

Affymetrix HuFL (5,600)

Muscle

4 JDM

Zhou and colleagues [6]

cDNA (4,000)

Muscle

6 PM, 4 DM

Greenberg and colleagues [7]

Affymetrix U133A (16,000)

Muscle

13 DM, 6 PM, 20 IBM

Raju and Dalakas [9]

Affymetrix U133A (16,000)

Muscle

3 DM, 4 IBM

Chen and colleagues [5]

Affymetrix U133A (16,000)

Muscle

31 JDM

Salajegheh and colleagues [8]

Affymetrix U133A (16,000)

Muscle

14 DM, 24 IBM, 38 PM/other

O'Connor and colleagues [16]

Quantitative real-time RT-PCR

Blood

14 JDM

Walsh and colleagues [24]

Affymetrix U133A 2.0+ (38,500)

Blood

12 DM, 11 PM, 13 IBM

Baechler and colleagues [23]

Affymetrix U133A 2.0+ (38,500)

Blood

10 DM, 2 JDM

Bilgic and colleagues [25]

Quantitative real-time RT-PCR

Blood

37 DM, 19 JDM

Liao and colleagues [26]

Affymetrix U133A 2.0+ (38,500)

Blood

24 DM, 12 PM, 15 IBM, 7 othera


aIncludes some previously published data. DM, dermatomyositis; IBM, inclusion body myositis; JDM, juvenile dermatomyositis; PM, polymyositis.

Baechler et al. Arthritis Research & Therapy 2011 13:249   doi:10.1186/ar3531